(S)-citalopram influences amygdala modulation in healthy subjects: A randomized placebo-controlled double-blind fMRI study using dynamic causal modeling

NeuroImage

Volumn 108, Issue , 2015, Pages 243-250

  Sladky, Ronald ^a   Spies, Marie ^b   Hoffmann, Andre ^a   Kranz, Georg ^b   Hummer, Allan ^a   Gryglewski, Gregor ^b   Lanzenberger, Rupert ^b   Windischberger, Christian ^a   Kasper, Siegfried ^b  

^a Christian Doppler Laboratory for Innovative Optical Imaging and its Translation to Medicine   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Amygdala; Citalopram; Dynamic causal modeling; Escitalopram; OFC; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ACCURACY; ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN MAPPING; COHORT ANALYSIS; CONNECTOME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYNAMIC CAUSAL MODELING; EMOTION; FACIAL EXPRESSION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; NEUROMODULATION; NORMAL HUMAN; ORBITAL CORTEX; PERCEPTIVE DISCRIMINATION; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; TASK PERFORMANCE; CHEMISTRY; DRUG EFFECTS; ISOMERISM; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; AMYGDALA; CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; ISOMERISM; MAGNETIC RESONANCE IMAGING; MALE; SEROTONIN UPTAKE INHIBITORS;

EID: 84922673013     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.12.044     Document Type: Article

References (62)

1. Abler B., Seeringer A., Hartmann A., Gron G., Metzger C., Walter M., Stingl J. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology 2011, 36:1837-1847.
2. Abler B., Gron G., Hartmann A., Metzger C., Walter M. Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs. J. Neurosci. 2012, 32:1329-1335.
3. Agustin-Pavon C., Braesicke K., Shiba Y., Santangelo A.M., Mikheenko Y., Cockroft G., Asma F., Clarke H., Man M.S., Roberts A.C. Lesions of ventrolateral prefrontal or anterior orbitofrontal cortex in primates heighten negative emotion. Biol. Psychiatry 2012, 72:266-272.
4. Almeida J.R., Versace A., Mechelli A., Hassel S., Quevedo K., Kupfer D.J., Phillips M.L. Abnormal amygdala-prefrontal effective connectivity to happy faces differentiates bipolar from major depression. Biol. Psychiatry 2009, 66:451-459.
5. Anand A., Li Y., Wang Y., Gardner K., Lowe M.J. Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J. Neuropsychiatry Clin. Neurosci. 2007, 19:274-282.
6. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 1999, 160:1-12.
7. Banks S.J., Eddy K.T., Angstadt M., Nathan P.J., Phan K.L. Amygdala-frontal connectivity during emotion regulation. Soc. Cogn. Affect. Neurosci. 2007, 2:303-312.
8. Bigos K.L., Pollock B.G., Aizenstein H.J., Fisher P.M., Bies R.R., Hariri A.R. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 2008, 33:3221-3225.
9. Buxton R.B., Wong E.C., Frank L.R. Dynamics of blood flow and oxygenation changes during brain activation: the balloon model. Magn. Reson. Med. 1998, 39:855-864.
10. Carballedo A., Scheuerecker J., Meisenzahl E., Schoepf V., Bokde A., Moller H.J., Doyle M., Wiesmann M., Frodl T. Functional connectivity of emotional processing in depression. J. Affect. Disord. 2011, 134:272-279.
11. Cipriani A., Santilli C., Furukawa T.A., Signoretti A., Nakagawa A., McGuire H., Churchill R., Barbui C. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst. Rev. 2009, CD006532.
12. Dolan R.J. The human amygdala and orbital prefrontal cortex in behavioural regulation. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2007, 362:787-799.
13. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., Mathis C. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 2007, 34:865-877.
14. Faria V., Appel L., Ahs F., Linnman C., Pissiota A., Frans O., Bani M., Bettica P., Pich E.M., Jacobsson E., Wahlstedt K., Fredrikson M., Furmark T. Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology 2012, 37:2222-2232.
15. Friston K.J., Harrison L., Penny W. Dynamic causal modelling. NeuroImage 2003, 19:1273-1302.
16. Frodl T., Bokde A.L., Scheuerecker J., Lisiecka D., Schoepf V., Hampel H., Moller H.J., Bruckmann H., Wiesmann M., Meisenzahl E. Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. Biol. Psychiatry 2010, 67:161-167.
17. Fusar-Poli P., Allen P., Lee F., Surguladze S., Tunstall N., Fu C.H.Y., Brammer M.J., Cleare A.J., McGuire P.K. Modulation of neural response to happy and sad faces by acute tryptophan depletion. Psychopharmacology 2007, 193:31-44.
18. Godlewska B., Norbury R., Selvaraj S., Cowen P., Harmer C. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol. Med. 2012, 42:2609-2617.
19. Gottfried J.A., O'Doherty J., Dolan R.J. Encoding predictive reward value in human amygdala and orbitofrontal cortex. Science 2003, 301:1104-1107.
20. Gray N.A., Milak M.S., Delorenzo C., Ogden R.T., Huang Y.-Y., Mann J.J., Parsey R.V. Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol. Psychiatry 2013, 1-6.
21. Hahn A., Stein P., Windischberger C., Weissenbacher A., Spindelegger C., Moser E., Kasper S., Lanzenberger R. Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. NeuroImage 2011, 56:881-889.
22. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297:400-403.
23. Haxby J.V., Hoffman E.A., Gobbini M.I. Human neural systems for face recognition and social communication. Biol. Psychiatry 2002, 51:59-67.
24. Hiemke C., Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 2000, 85:11-28.
25. Hindi Attar C., Finckh B., Büchel C. The influence of serotonin on fear learning. PLoS ONE 2012, 7:e42397.
26. Hornboll B., Macoveanu J., Rowe J., Elliott R., Paulson O.B., Siebner H.R., Knudsen G.M. Acute serotonin 2A receptor blocking alters the processing of fearful faces in the orbitofrontal cortex and amygdala. J. Psychopharmacol. 2013, 27(10):903-914.
27. Hyttel J. Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5- HT uptake in rat brain synaptosomes in vitro. Psychopharmacology 1978, 60:13-18.
28. John Y.J., Bullock D., Zikopoulos B., Barbas H. Anatomy and computational modeling of networks underlying cognitive-emotional interaction. Front. Hum. Neurosci. 2013, 7:101.
29. Kasess C.H., Stephan K.E., Weissenbacher A., Pezawas L., Moser E., Windischberger C. Multi-subject analyses with dynamic causal modeling. NeuroImage 2010, 49:3065-3074.
30. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62:593.
31. Kim D., Paré D., Nair S.S. Mechanisms contributing to the induction and storage of Pavlovian fear memories in the lateral amygdala. Learn. Mem. 2013, 20:421-430.
32. Klein N., Sacher J., Geiss-Granadia T., Attarbaschi T., Mossaheb N., Lanzenberger R., Pötzi C., Holik A., Spindelegger C., Asenbaum S., Dudczak R., Tauscher J., Kasper S. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology 2006, 188:263-272.
33. Klein N., Sacher J., Geiss-granadia T., Lanzenberger R., Spindelegger C., Holik A., Asenbaum S., Dudczak R., Tauscher J., Kasper S. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [ 123 I ] ADAM SPECT study. Psychopharmacology 2007, 191:333-339.
34. Kranz G.S., Kasper S., Lanzenberger R. Reward and the serotonergic system. Neuroscience 2010, 166:1023-1035.
35. Liao W., Qiu C., Gentili C., Walter M., Pan Z., Ding J., Zhang W., Gong Q., Chen H. Altered effective connectivity network of the amygdala in social anxiety disorder: A resting-state fMRI study. PLoS ONE 2010, 5:e15238.
36. Mathew S.J., Price R.B., Charney D.S. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 2008, 89-98. John Wiley & Sons.
37. McCabe C., Mishor Z. Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. NeuroImage 2011, 57:1317-1323.
38. Merens W., Willem Van Der Does A.J., Spinhoven P. The effects of serotonin manipulations on emotional information processing and mood. J. Affect. Disord. 2007, 103:43-62.
39. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. Rev. Psychiatry Neurosci. 2007, 32:86-102.
40. Moltke L.v., Greenblatt D., Giancarlo G., Granda B., Harmatz J., Shader R. Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comarison to R-citalopram. Drug Metab. Dispos. 2001, 29:1102-1109.
41. Moulin-Sallanon M., Charnay Y., Ginovart N., Perret P., Lanfumey L., Hamon M., Hen R., Fagret D., Ibáñez V., Millet P. Acute and chronic effects of citalopram on 5-HT1A receptor-labeling by [18F]MPPF and -coupling to receptors-G proteins. Synapse 2009, 63:106-116.
42. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluogetine. Biol. Psychiatry 2001, 345-350.
43. Parks C.L., Robinson P.S., Sibille E., Shenk T., Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10734-10739.
44. Penny W.D., Stephan K.E., Daunizeau J., Rosa M.J., Friston K.J., Thomas M., Leff A.P. Comparing families of dynamic causal models. PLoS Comput. Biol. 2010, 6.
45. Phan K.L., Fitzgerald D.A., Nathan P.J., Tancer M.E. Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol. Psychiatry 2006, 59:424-429.
46. Phillips M.L., Ladouceur C.D., Drevets W.C. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol. Psychiatry 2008, 13(829):833-857.
47. Ramboz S., Oosting R., Amara D.A., Kung H.F., Blier P., Mendelsohn M., Mann J.J., Brunner D., Hen R. Serotonin receptor 1A knockout: An animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14476-14481.
48. Robinson S., Windischberger C., Rauscher A., Moser E. Optimized 3T EPI of the amygdalae. NeuroImage 2004, 22:203-210.
49. Sánchez C., Bergqvist P.B.F., Brennum L.T., Gupta S., Hogg S., Larsen A., Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003, 167:353-362.
50. Scheidegger M., Walter M., Lehmann M., Metzger C., Grimm S., Boeker H., Boesiger P., Henning A., Seifritz E. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS ONE 2012, 7:e44799.
51. Schuyler B., Ollinger J.M., Oakes T.R., Johnstone T., Davidson R.J. Dynamic causal modeling applied to fMRI data shows high reliability. NeuroImage 2010, 49:603-611.
52. Seghier M.L., Zeidman P., Neufeld N.H., Leff A.P., Price C.J. Identifying abnormal connectivity in patients using dynamic causal modeling of FMRI responses. Front. Syst. Neurosci. 2010, 4:1-14.
53. Shin L.M., Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010, 35:169-191.
54. Shrestha S., Hirvonen J., Hines C.S., Henter I.D., Svenningsson P., Pike V.W., Innis R.B. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. NeuroImage 2011, 59:3243-3251.
55. Sladky R., Höflich A., Atanelov J., Kraus C., Baldinger P., Moser E., Lanzenberger R., Windischberger C. Increased neural habituation in the amygdala and orbitofrontal cortex in social anxiety disorder revealed by FMRI. PLoS ONE 2012, 7:e50050.
56. Sladky R., Höflich A., Küblböck M., Kraus C., Baldinger P., Moser E., Lanzenberger R., Windischberger C. Disrupted effective connectivity between the amygdala and orbitofrontal cortex in social anxiety disorder during emotion discrimination revealed by dynamic causal modeling for fMRI. Cereb. Cortex 2013, 10.1093/cercor/bht279.
57. Spindelegger C., Lanzenberger R., Wadsak W., Mien L.K., Stein P., Mitterhauser M., Moser U., Holik A., Pezawas L., Kletter K., Kasper S. Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol. Psychiatry 2009, 14:1040-1050.
58. Stephan K.E., Penny W.D., Moran R.J., den Ouden H.E.M., Daunizeau J., Friston K.J. Ten simple rules for dynamic causal modeling. NeuroImage 2010, 49:3099-3109.
59. Tottenham N., Tanaka J.W., Leon A.C., McCarry T., Nurse M., Hare T.A., Marcus D.J., Westerlund A., Casey B.J., Nelson C. The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res. 2009, 168:242-249.
60. Wellman C.L., Izquierdo A., Garrett J.E., Martin K.P., Carroll J., Millstein R., Lesch K.-P., Murphy D.L., Holmes A. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 2007, 27:684-691.
61. Windischberger C., Lanzenberger R., Holik, A.l., Spindelegger C., Stein P., Moser U., Gerstl F., Fink M., Moser E., Kasper S. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. NeuroImage 2010, 49:1161-1170.
62. Yevtushenko V.Y., Belous A.I., Yevtushenko Y.G., Gusinin S.E., Buzik O.J., Agibalova T.V. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin. Ther. 2007, 29:2319-2332.